Royalty Report: Drugs, cardiac, Therapeutic – Collection: 6956


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • cardiac
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Cancer
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6956

License Grant
Licensor grants the Company an exclusive license to Patent Rights in the Territory with the right to sublicense the Licensed Intellectual Property to research, develop, use, manufacture, have manufactured, sell, offer to sell or have sold Licensed Products; and OptiVax as it relates to use in the Field.
License Property
Licensor has developed Know-How and has Patent Rights in the fields of the composition and use of surface-active copolymers exemplified by poloxamer 188 to treat ischemic or damaged tissue, myocardial damage, stroke, pathological hydrophobic interactions in biological fluids, tissue damaged by reperfusion injury, sickle cell disease, cancer and in performing angioplasty procedures, referred to collectively as the Flocor Intellectual Property;  the composition and use of surface active copolymers (exemplified by poloxamers, reverse poloxamers and diether, diester or diamide fatty acid conjugates of poloxyethylene) to treat infections caused by microorganisms, including bacteria, fungi, and viruses and to treat tumors, field referred to collectively as the Anti-Infectives Intellectual Property; and conventional vaccine adjuvants exemplified by poloxamer P1005, referred to collectively as the OptiVax Intellectual Property.

Licensor and the Company wish to continue the development and subsequent commercialization of the Flocor Intellectual Property, the Anti-Infectives Intellectual Property and the OptiVax Intellectual Property pursuant to a license to be granted by Licensor to Company.

Patent Rights shall mean all United States or foreign patents or patent applications, and patents to be issued pertaining to Flocor, the Anti-Infectives or Optivax, excluding the use in certain fields;  or are divisions, continuations, reissues, renewals, extensions, supplementary protection certificates, utility models and the like of any such United States patents and patent applications and foreign equivalents thereof.

OptiVax shall mean novel  polyoxyethylene/polyoxypropylene copolymers that are high molecular weight molecules and are useful as vaccine adjuvants.

Flocor shall mean surface-active copolymers of an ethylene oxide-propylene oxide condensation products that have cytoprotective, rheologic and antithrombotic activities exemplified by poloxamer 188.

Anti-Infectives shall mean polyoxypropylene/polyoxyethylene copolymers and other polyoxyethylene conjugates having therapeutic activity or having the ability to enhance the therapeutic activity of other agents against infective organisms, including bacteria, viruses and fungi.

Field of Use
Field shall mean the use of Licensed Intellectual Property in all fields for Flocor, Anti-Infectives and OptiVax Agreements, except for those fields of use that are or will be licensed under the Licensor Licenses set forth in recital A to this Agreement.

IPSCIO Record ID: 4279

License Grant
The Licensee entered into a License Agreement with the Licensor.

The Licensee is obligated to pay a royalty on sales under the License for the Flocor Intellectual Property, also on sales under the License for Anti-Infectives Intellectual Property and on sales under the License for OptiVax Intellectual Property.

License Property
Upon attainment of certain milestones, which include regulatory approvals and first commercial sales, the Licensee may be obligated to pay fees of up to $8,000,000.
Field of Use
Flocor is an amphipathic copolymer, as a potential treatment for acute sickle cell crisis and acute respiratory distress syndrome (ARDS)/acute lung injury. Flocor has rheologic, cytoprotective, anti-adhesive and antithrombotic effects and has potential in the treatment of acute ischemic vascular disorders such as stroke and myocardial infarction (MI).

IPSCIO Record ID: 7755

License Grant
The Licensor hereby grants to the Licensee an exclusive license in the Territory with the right to sublicense under the Patent Rights to research, develop, use, manufacture, have manufactured, sell, offer to sell or have sold TranzFect as it relates to use with Substance in the Field; and Licensed Product. Included is the right to Sublicense.
License Property
The Licensor has rights to Patents Rights collectively referred to as Poloxamer Intellectual Property.

The term PSMA shall mean all compositions and uses of, collectively molecules that elicit an immune response specific for prostate specific membrane antigen.

The term TranzFect shall mean any polyoxypropylene/polyoxyethylene copolymer compound or compositions or preparations of such compounds claimed in or covered by CytRx Poloxamer Intellectual Property that may be added to Substance to enhance performance of such Substance relative to use of the Substance without Tranzfect.

US PATENT 5,554,372  Methods and vaccines comprising surface-active copolymers
US PATENT 6,086,899  Ethylene oxide-propylene oxide copolymer
US PATENT 5,824,322  Compositions and methods for growth promotion

Field of Use
Field shall mean the use of Licensor Poloxamer Intellectual Property limited to protein, DNA or viral vaccines based on Licensee for use in any human therapeutic and/or prophylactic medical use.

Licensee will enter research and development activities related to the use of Transfect in the Field, to develop and commercialize a Licensed Product on a commercially reasonable basis.

IPSCIO Record ID: 213335

License Grant
Seller desires to sell, transfer and assign to Buyer certain assets related to the vepoloxamer product candidate including all tangible and intangible property related to polyoxyethylene containing surface-active agents owned or controlled by Seller as of the Effective Date. Vepoloxamer is used for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in development for the treatment of patients with heart failure.  US Patents 9757411;  9,403,941 are included in the assets.
License Property
Seller holds certain rights to a discontinued vepoloxamer product candidates use in cardiac disease. Storage Product means a for use in the ex vivo storage of cells intended for future transplant or transfusion into patients. Therapeutic Product is for direct administration to a patient for the treatment of a medical condition.
Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.